Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05985863 |
|
Recruitment Status :
Recruiting
First Posted : August 14, 2023
Last Update Posted : May 7, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Acute-On-Chronic Liver Failure | Drug: standard medical treatment Drug: Placebo Drug: hUC-MSC Drug: hUC-MSC_Prolonged | Phase 1 Phase 2 |
Acute-on-chronic liver failure (ACLF) has been proposed to define a distinct syndrome which is characterized by an intense systemic inflammatory response, single- or multiple organ system failures, and high 28-day mortality. Current treatments for liver failure are still limited, and liver transplantation remains the only available approach to improve survival but is restricted by a shortage of organ resources, rejection after transplantation, and heavy financial costs. In the past decade, a series of new applications based on mesenchymal stem cell (MSC) therapy have been studied as an alternative interventional method for chronic liver diseases. This randomized double-blind placebo-controlled multicenter clinical trial is aimed at determining the safety and clinical efficacy of UC-MSC transfusions in ACLF patients.
A total of 150 ACLF patients would be enrolled,100patients would be assigned to the MSC intervention group and the other 50 patients would be assigned to the placebo control group. This trial is two-stage randomized designed. At the first stage, the patients would be randomized into two groups, the placebo short control group would receive standard medical treatment plus 3 times placebo (at week0, week1 and week2), while the MSC short treatment group would receive standard medical treatment plus 3 times hUC-MSC (1.5×10^8, Peripheral IV, at week0, week1 and week2). The two groups would be followed up for 2 weeks, and unblinding would be conducted at week4. At the second stage, the survived patients of the MSC short treatment group would be further randomized and blinded into another two groups. The MSC Prolonged treatment group would receive another 2 times hUC-MSC (1.5×10^8, Peripheral IV, at week4 and week5), while the MSC Prolonged control group would receive 2 times placebo (at week4 and week5).
Transplantation free survival rate and incidence of treatment-emergent adverse events would be the primary outcomes, and other outcomes such as international normalized ratio (INR), total bilirubin (TBIL, mg/dL), serum albumin (ALB, g/L), blood urea nitrogen (BUN, mmol/l), the model for end-stage liver disease(MELD) score and child-turcotte-pugh(CTP) score would also be measured.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 150 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Clinical Research of Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure |
| Actual Study Start Date : | September 30, 2023 |
| Estimated Primary Completion Date : | December 30, 2026 |
| Estimated Study Completion Date : | December 30, 2028 |
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Group Control
standard medical treatment+Placebo(5% human serum albumin in 0.9% saline, at week0, week1 and week2)
|
Drug: standard medical treatment
standard medical treatment for ACLF Drug: Placebo 5% human serum albumin in 0.9% saline (at week0, week1 and week2) |
|
Experimental: Group MSC-1
Patients received standard medical treatment and infusions of hUC-MSC(1.5×10^8) via peripheral veins once a week for 3 timess(at week0, week1, and week2).
|
Drug: standard medical treatment
standard medical treatment for ACLF Drug: hUC-MSC hUC-MSC (1.5×10^8 cells/time, Peripheral IV, at week0, week1 and week2) |
|
Experimental: Group MSC-2
Patients in Group MSC-1 received standard medical treatment and infusions of hUC-MSC(1.5×10^8) via peripheral veins once a week for another 2 timess(at week4 and week5).
|
Drug: standard medical treatment
standard medical treatment for ACLF Drug: hUC-MSC hUC-MSC (1.5×10^8 cells/time, Peripheral IV, at week0, week1 and week2) Drug: hUC-MSC_Prolonged hUC-MSC (1.5×10^8 cells/time, Peripheral IV, at week4 and week5) |
- Transplantation free survival rate [ Time Frame: week1, week2, week3, week4, week5, week8, week12, week24, week53 ]Transplantation free survival rate of ACLF patients.
- Incidence of Treatment-Emergent Adverse Events [ Time Frame: day0, day3, week1, week2, week3, week4, week5, week8, week12, week24, week53 ]Safety and Tolerability of UC-MSCs transplantation.
- International Normalized Ratio (INR) [ Time Frame: week-1, week0, day3, week1, week2, week3, week4, week5, week12, week24, week53 ]INR was introduced as a standardized reporting mechanism allowing comparisons across laboratories and patients. Consensus guidelines recommend that INR ≥ 1.5 can be used as a threshold, and current recommendations for targeting an INR of < 1.5 were based on studies across all surgical disciplines.
- Concentration of Total Bilirubin (TBIL, mg/dL) [ Time Frame: week-1, week0, day3, week1, week2, week3, week4, week5, week12, week24, week53 ]Total bilirubin refers to the concentration of bilirubin in a patient's blood sample, which is automatically measured by the laboratories in accordance with standard operating procedures. APASL defines ACLF as "an acute hepatic insult manifesting as jaundice (Serum Bilirubin ≥ 5 mg/dL) and coagulopathy (international normalized ratio [INR] ≥ 1.5) complicated within 4 weeks by clinical ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease/cirrhosis, that is associated with a high 28-day mortality."
- Concentration of Serum Albumin (ALB, g/L) [ Time Frame: week-1, week0, day3, week1, week2, week3, week4, week5, week12, week24, week53 ]Serum albumin refers to the concentration of albumin in a patient's serum, which is automatically measured by the laboratory in accordance with standard operating procedures. Serum albumin is an independent protective factor for 30-day prognosis in ACLF patients.
- Concentration of Blood Urea Nitrogen (BUN, mmol/L) [ Time Frame: week-1, week0, day3, week1, week2, week3, week4, week5, week12, week24, week53 ]Blood urea nitrogen refers to the concentration of urea nitrogen in a patient's blood sample. Blood urea nitrogen is a commonly used indicator of renal function in clinic.
- The Model for End-Stage Liver Disease(MELD) score [ Time Frame: week-1, week1, week2, week4, week5, week12, week24, week53 ]R = 3.8×ln [TBiL (mg/dl)] +11.2×ln (INR) +9.6×ln [Cr (mg/dl)] +6.4× (Cause: biliary or alcoholic is 0, other is 1), the result is taken as an integer. Studies have shown that the optimal critical value of MELD score to judge the short-term prognosis of ACLF patients is 30, and when MELD score is greater than 30, the case fatality rate of patients within 3 months is significantly increased.
- Child-Turcotte-Pugh(CTP) score [ Time Frame: week-1, week1, week2, week4, week5, week12, week24, week53 ]CTP score is currently the most commonly used model to evaluate liver reserve function and prognosis in patients with cirrhosis. This model evaluates liver function based on HE grade, degree of abdominal fluid accumulation, bilirubin (TBiL), albumin (Alb) and prothrombin time (PT). The score ranges from 0 to 15, with the higher the score, the worse the prognosis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 years old ≤ age ≤ 70 years old, gender is not limited.
- Meet the APASL definition of ACLF: acute liver injury in patients with previously diagnosed or undiagnosed chronic liver disease or cirrhosis, manifested as jaundice (total bilirubin levels of 5 mg/dl or more) and coagulopathy (INR of 1.5 or more, or prothrombin activity of less than 40%） complicated within 4 weeks by clinical ascites, encephalopathy, or both.
- Willing to sign the informed consent form.
Exclusion Criteria:
- Patients with acute kidney injury, upper gastrointestinal hemorrhage, hepatic encephalopathy above grade II (inclusive) or uncontrolled infection at baseline;
- Before the onset of liver failure, the previous indicators of the patient included PLT<50×10^9/L or Child-Pugh score>9;
- Combined with liver cancer or other malignant tumors;
- Patients with previous liver transplantation or planned liver transplantation within 3 months;
- Severe organic disease of primary extrahepatic organs;
- Those who have a history of venous thrombosis or pulmonary embolism are judged by the investigator to be ineligible to participate in this trial;
- Pregnant, breastfeeding women or those who plan to have a baby in the near future;
- Those who are highly allergic or have a history of severe allergies;
- Those who have received immunosuppressant and immune enhancer treatment within 1 month;
- Drug abuse in the past 5 years;
- Alcohol withdrawal symptoms;
- A history of severe mental disorders within 24 months before screening, including uncontrolled major depression or controlled or uncontrolled psychosis;
- Those who have participated or are participating in other clinical trials within three months before screening, or have previously received stem cell therapy;
- Other conditions that the investigator thinks that the patient is not suitable to participate in this study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05985863
| Contact: Tao Yang, MD | 86-010-66933333 | y_t_0321@163.com | |
| Contact: Yanhu Wang, MM | 86-010-66933328 | 2440477984@qq.com |
| China, Beijing | |
| the Fifth Medical Center, Chinese PLA General Hospital | Recruiting |
| Beijing, Beijing, China, 100039 | |
| Contact: Tao Yang, MD 010-66933333 y_t_0321@163.com | |
| Contact: Mengyao Li, MB 010-66933333 qianlimengyao@163.com | |
| Principal Investigator: | Ming Shi, PhD | the Fifth Medical Center, Chinese PLA General Hospital |
| Responsible Party: | Shi Ming, Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 302 Hospital |
| ClinicalTrials.gov Identifier: | NCT05985863 |
| Other Study ID Numbers: |
2022YFC2304402 |
| First Posted: | August 14, 2023 Key Record Dates |
| Last Update Posted: | May 7, 2024 |
| Last Verified: | May 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Mesenchymal Stem Cells Acute-On-Chronic Liver Failure Therapeutics |
|
Liver Failure Hepatic Insufficiency End Stage Liver Disease Acute-On-Chronic Liver Failure |
Liver Diseases Digestive System Diseases Liver Failure, Acute |